TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07775404: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (

Sponsor: AstraZeneca · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 351 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,314,560

Rescue Site Savings

+$7,448,752

Unlock Full NCT07775404 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07775404 Rescue Dossier →